1 DNA methylation biomarker in blood predicts frailty 2 in an HIV-positive veteran population 3 Chang Shu^{1,2}, Amy C. Justice^{1,2}, Xinyu Zhang^{1,2}, Vincent C. Marconi³, Dana B. 4 Hancock⁴, Eric O. Johnson^{4,5}, Ke Xu^{1,2} 5 6 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06516 7 2. Connecticut Veteran Healthcare System, West Haven, CT, 06515 8 3. Division of Infectious Disease, Emory University School of Medicine, Atlanta GA 9 4. Center for Omics Discovery and Epidemiology, Behavioral Health Research Division, 10 RTI International, Research Triangle Park, NC, USA 11 5. Fellow Program, RTI International, Research Triangle Park, NC, USA. 12 13 All corresponding address to 14 Ke Xu, M.D., Ph.D. Associate Professor of Psychiatry 15 16 Yale School of Medicine 17 Email: ke.xu@yale.edu

18

Tel: 203-932-5711x7430

Abstract

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Background: With the improved life expectancy in people living with HIV, predicting individual frailty is important for clinical care. DNA methylation (DNAm) has emerged as a robust biomarker in precision medicine and has been previously linked to aging and mortality in non-HIV populations. Here, we aim to establish a panel of DNAm features selected from blood methylome to predict frailty in HIV-positive men from a veteran population, Veterans Aging Cohort Study (VACS). **Methods**: We used a well-established score, VACS Index, as a measure of frailty. Samples (n_{total}=1,150) were divided into a training set (n=612) and a validation set (n=538). We first selected a panel of frailty-associated CpGs by conducting an epigenome-wide association analysis on the VACS index in the training set. We then applied four machine learning methods to build models to predict high and low frailty individuals in the training set. The prediction models were tested in the validation set. A methylation score constructed from the selected CpGs was tested an associated with mortality by performing survival analysis. To assess the biological relevance of the selected CpG sites, we performed a gene ontology enrichment analysis. Results: A panel of 119 CpGs were identified from the training set (False Discovery Rate <0.2) that showed excellent performance on predicting high frailty individuals with Area Under Curve (AUC) of 0.835 (95%CI: 0.792, 0.879) and balanced accuracy of 0.693. The same panel showed good performance on predicting low frailty individuals with AUC of 0.735 (95%CI: 0.688-0.782) and a balanced accuracy of 0.528. The methylation score from the 119 CpGs was significantly associated with 5-year and 10year mortality with hazard ratio of 1.40 (95% CI:1.033, 1.897 p=0.03) and 1.48 (95%CI:

42 1.10, 2.02; p=0.01) respectively. These 119 CpGs were located within or near 73 genes 43 that were significantly enriched in 9 biological pathways relevant to immune and 44 inflammation response. 45 **Conclusions:** We identified a panel of predictive DNAm features associated with frailty 46 and mortality among HIV-positive population. These DNAm features may serve as 47 biomarkers to discriminate high and low frailty people who live with HIV. 48 49 **Keywords:** DNA methylation, HIV-positive, frailty, mortality, DNA methylation score, 50 machine learning prediction 51

Background

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Combination antiretroviral therapy has significantly improved life expectancy among HIV-positive individuals. The prolonged life expectancy increases frailty risk in the HIV population. The prevalence of frailty in people living with HIV is significantly higher and onset of frailty occurs at an earlier age compared to the general population (1). High frailty is characterized by marked vulnerability and is associated with increased mortality. Thus, prediction of frailty is important to identify vulnerable group and deliver clinical care to highly vulnerable HIV-positive patients. At present, frailty is usually defined by clinical symptoms (e.g., Fried's frailty phenotype, Rockwood and Mitnitski's Frailty Index) or a combination of lab tests that indicate organ damage such as the Veterans Aging Cohort Study index (VACS index) (2). No biomarkers available to capture the early stage of the frailty to predict individual vulnerability in HIV-positive patients. A large body of evidence has demonstrated that epigenetic modification adapts internal and external environmental changes and that is associated with early stage of pathophysiological processes (3-6). DNAm, one type of the most widely studied epigenetic marks, is strongly related with aging (7-9), substance use (e.g. cigarette smoking and alcohol consumption) (10-16), and a variety of diseases (3-6, 17, 18). Because DNAm is relatively stable and easy to detect from body fluids biospecimen through non-invasive procedure, DNAm marks have emerged as robust biomarkers for cancer diagnosis (19), disease subtype classification (20, 21) and treatment response monitoring (22, 23).

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

DNAm may play an important role in frailty among HIV-positive individuals. Frailty is associated with elevated inflammation markers such as IL-6 and hsCRP in HIVpositive individuals (24). Genes involved in immune and inflammation processes are also subject to epigenetic modification in immune cells. We previously reported association of two CpG sites in the promoter region of NLRC5 with HIV infection (25). and NLRC5 gene is a major transcriptional activator of MHC class I gene. DNAm was also linked to HIV comorbid medical diseases such as HIV-positive diabetes and kidney function (26, 27). Furthermore, aging, a critical contributor to frailty, is significantly associated with thousands of CpGs in the epigenome, and the epigenetic clock and DNAm age are becoming widely recognized (7-9). DNAm age is significantly correlated with physical frailty in HIV-negative individuals (28) and HIV-positive individuals (29). In HIV-positive individuals, the average DNAm age is accelerated 5 to 10 years faster than HIV-negative individuals (30-33) and 10 years faster in the HIV-positive frailty individuals in comparing to HIV-positive non-frailty individuals (29). These age-related DNAm signatures are predictive of mortality (34-38). Additional CpGs in blood have been identified to predict all-cause mortality (34, 39). Therefore, we hypothesize that DNAm is associated with frailty and that DNAm signatures in blood can serve as biomarkers to predict frailty and mortality among HIV-positive individuals. In this study, our goal is to identify DNAm marks that can serve as biomarkers on frailty and to link frailty-associated DNAm to mortality among HIV-positive individuals. We also evaluated biological relevance of the identified CpG sites. We used a well-established frailty score, VACS index, as a measure of frailty in the HIV-positive population. The VACS index is a composite score constructed by a sum of pre-assigned

points on age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine transaminase (AST and ALT), creatine, estimated glomerular filtration rate (eGFR), and viral hepatitis C infection (40). Findings from this study provide a set of DNAm biomarkers to predict frailty for future clinic use and new insights into the epigenetic mechanism of frailty and mortality in HIV pathology.

Methods

As an overview, our analytical procedure is shown in the flowchart in **Figure 1**. Our sample was divided into the training set (n=612) and the validation set (n=538) which DNA methylation were processed at different time and using two different platforms. We first selected a panel of CpG sites relevant to frailty based on EWAS results in the training set. Then, we applied four commonly used machine learning classification methods to develop prediction models: random forest, Extreme Gradient Boosting Tree (XGBoost), Lasso and Elastic-Net Regularized Generalized Linear Models (GLMNET), and Support Vector Machines (SVM). The selected CpG sites were used as predictors to differentiate high and low frailty in the training set and each model was evaluated in the validation set. Additionally, the DNAm score was constructed based on the selected CpG sites and we conducted survival analysis to assess whether the DNAm score was associated with mortality in the HIV-positive samples. Lastly, we conducted a gene ontology enrichment analysis to reveal the underlying biological pathways of the selected CpG sites.

Study population

All samples in the training and validating sets were from the VACS cohort. The VACS is a prospective cohort study of veterans focusing on clinical outcomes in HIV infection (41). DNA samples were extracted from peripheral blood of 1,150 HIV-positive men from the VACS. Demographic and clinical information on age, race, smoking status, CD4 count, viral load, HIV medication adherence, VACS index, and mortality by training set and validation set are presented in **Table 1**. The training set included slightly older individuals, more African Americans, and greater VACS index than the validation set. There was no significant difference in HIV medication adherence, CD4 count, or log₁₀ HIV-1 viral load between the training set and the validation set.

Table 1: Study sample characteristics

Table 1. Study Sample Characte	Training set	Validation set	
	(N=612)	(N=538)	p value*
Age (year, mean +/-sd)	49.4 (7.6)	48.1 (7.8)	0.005
Male (%)	612 (100)	538 (100)	
Race (%)			
Caucasian	58 (9.5)	48 (8.9)	0.001
African Americans	526 (85.9)	435 (80.9)	
Other	28 (4.6)	55 (10.2)	
Smokers (%)	360 (59.4)	309 (58.4)	0.78
HIV positive (%)	614 (100)	538 (100.0)	
HIV treatment adherence			
(%)	469 (78.4)	407 (76.6)	0.519
CD4 count	428.97 (286.33)	447.46 (279.27)	0.287
log 10 HIV-1 viral load	2.61 (1.19)	2.67 (1.23)	0.423
VACS index (mean +/-)	35.64 (21.99)	30.78 (20.23)	< 0.001
Mortality (%)	162 (26.5)	129 (24.0)	0.367

^{*}t test is used for continous variables, chi-square test is used for categorical variables

Genome-wide DNAm profiling and quality control

The DNA samples in the training set were profiled by Infinium Human Methylation 450K BeadChip (HM450K) and the DNA samples in the validation set were profiled by the

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Infinium Human Methylation EPIC BeadChip. DNAm for the training and validation sets were evaluated using the same quality control (QC) protocol (42) in the R package minfi (43). In detail, CpG sites on sex chromosomes and within 10 base pairs of a single nucleotide polymorphism were removed. The detection p-value threshold was set at 10⁻¹ ¹² for both the training and validation sets. After QC, 408,583 shared CpG sites between HM450K and EPIC arrays were used for analysis to ensure the same coverage between two sets. Proportions of 6 cell types (CD4+ T cells, CD8+ T cells, Natural Killer T cells, B cells, monocytes and granulocytes) were estimated using the established method (Houseman et al., 2012) for all samples in the training and validation sets. Selection of CpG sites from EWAS on frailty in the training set We performed an EWAS on VACS index in the training set using a two-step linear model approach as previously described (42). The analytical model was adjusted for systematic errors and clinical confounding factors. Here, log transformation was applied to VACS index to ensure normality distribution assumption for the linear model. First, the following linear model was used to extract principal components (PCs) for potential confounding variables. Here, top 30 control PCs were derived from internal control probes in *minfi*: Methylation $\beta \sim$ age + race + smoking + self-reported HIV medication adherence + log viral load + WBC + CD4T + CD8T + Gran + NK + B cell + Mono + 30 Control PCs Second, the top 20 residual PCs were extracted in the model above to fully adjust for unmeasured confounding. The final EWAS model on VACS index was:

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

log(VACS) ~ Methylation β + age + race + smoking + self-reported HIV medication adherence + log viral load + WBC + CD4T + CD8T + Gran + NK + B cell + Mono + 30 Control PCs + 20 Residual PCs To ensure a sufficient number of CpGs as predictors for the prediction model development, we selected CpG sites with false discovery rate (FDR) < 0.2 in the EWAS as predictors. Additionally, to explore the underlying epigenetic mechanism of frailty, we also detected differentially methylated regions (DMRs) using bumpHunter (44) in the training set. DMRs with family-wise error rate (FWER)<0.2, which is equivalent to FDR<0.03, were considered significant. Developing machine learning prediction models for frailty Based on the distribution of the VACS index in the entire sample (Figure S1) and clinical significance (45), high HIV frailty was defined as VACS index > 50, and low HIV frailty was defined as VACS index < 16. Models were developed to predict high frailty (VACS index >50 versus ≤50) and low frailty (VACS index <16 versus ≥16). CpGs relevant to frailty were selected from EWAS as described above. The following steps were taken to develop separate prediction models on high and low frailty: 1) Model development in the training set: Four machine learning models, random forest, Extreme Gradient Boosting Tree (XGBoost), support vector machines(SVM), Lasso and Elastic-Net Regularized Generalized Linear Models (GLMNET), were separately applied to predict VACS index by using the R package caret (46). These four

models are commonly used in the supervised learning on classification (47-50). Each

model was developed separately and 10-fold cross-validation was used in model training process to minimize data overfitting.

2) Model evaluation in the validation set: All four models built in the training set were evaluated in the validation set. Area Under Curve (AUC) and balanced accuracy were used to assess the prediction performance. We used balanced accuracy for model evaluation because in the presence of imbalance samples in each class since there are 228 subjects with VACS index greater than or equal to 50 and 916 subjects with VACS index less than 916. Balanced accuracy is defined as the average accuracy obtained on each class as shown in the following formula (51). Balanced accuracy was used in this study to avoid biased accuracy due to imbalanced samples (51).

Balanced accuracy

$$= \frac{1}{2} \left(\frac{True\ positive}{True\ positive + False\ negative} + \frac{True\ negative}{True\ negative + False\ positive} \right)$$

Association of a DNAm score for VACS index with mortality

We constructed a DNAm score by the selected frailty-associated CpG sites. A survival analysis was conducted to assess whether the DNAm score was associated with 5-year and 10-year mortality respectively.

DNAm score was constructed based on a previously reported method (12). We computed the DNAm score by normalizing the score with mean β value (μ_c) and standard deviation, σ_c , from subjects with VACS index <50 (control group). For selected n methylation sites, W_c is 1 for a hypermethylated methylation site c, and -1 for a

hypomethylated site c, β_{ci} is the β value for subject i and methylation site c. The methylation score for subject i was constructed by the following formula:

200
$$Methylation Score_{i} = \frac{1}{n} \sum_{c=1}^{n} W_{c} \frac{\beta_{ci} - \mu_{c}}{\sigma_{c}}$$

The mean methylation score was 0, and samples were divided into high methylation score (>0) and low methylation score (\leq 0) groups.

We preformed Kaplan-Meier survival curves during 10-year follow-up to visualize the survival differences between high and low methylation score groups. Survival analysis was conducted by cox proportional hazards model on 5-year and 10-year mortality comparing high and low methylation groups. We used age as time scale t, and our model was adjusted for race, smoking, self-reported HIV medication adherence, log 10 of HIV viral load and CD4 count.

210
$$h(t) = h_0(t) \exp(\beta_1 \text{ methylation score} + \beta_2 \text{ race} + \beta_3 \text{ smoking}$$

211 $+ \beta_4 \text{ HIV medication adherence} + \beta_5 \log_{10}(\text{viral load}) + \beta_6 \text{ CD4 count})$

Biological interpretation of the predictive panel of CpG sites on frailty

We performed gene ontology (GO) enrichment analysis using Database for Annotation, Visualization and Integrated Discovery (DAVID) (52). To avoid redundancy in pathway names, we only used level 4 GO terms defined in DAVID in the enrichment analysis. Genes with at least one frailty-associated CpG site was used for GO analysis. We considered biological pathways with FDR <0.05 as statically significant pathways.

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

Results Selection a panel of 119 frailty-associated CpG sites by EWAS in the training set In the training set, we conducted an EWAS on VACS index (**Figure 2**; λ =1.038) and selected 119 CpGs with FDR<0.2 to ensure sufficient number of predictors (Table 2). Eighty out of 119 CpGs were negatively associated with VACS index, while 39 out of 119 CpGs were positively associated with VACS index. The majority of CpGs were located within or near known genes, except for 19 CpGs that were intergenic. Only 40 CpGs were located in gene bodies, while 79 CpGs were located in promoter regions, first exons, or 3' UTR. Thirty-two CpGs were located in CpG islands. Notably, 22 out of 119 CpGs reached epigenome-wide significance (FDR<0.05), including 16 CpG sites negatively associated with the VACS index and 6 CpG sites with positive associations. These 22 CpGs were located on 17 genes, including 13 of 22 CpGs located in promoter regions, 6 CpGs in gene body, and 3 CpGs in 3'UTR. Among these genes, some harbored more than one significant CpG. For example, three CpGs were annotated within or near *PSMB8* (cq01309328, p= 4.44×10^{-9} ; cq08099136, $p=4.63\times10^{-9}$; cg00533183, p=3.18×10⁻⁷), two CpGs were located near *PARP*9 $(cg08122652, p=2.18\times10^{-7}; cg22930808, p=6.78\times10^{-7}), two CpG sites were located$ near *IFITM1* (cg03038262, p= 5.83×10^{-7} ; cg23570810, p= 1.58×10^{-6}), and the rest of the significant CpG sites were annotated to 13 genes including MX1, TAP1, ZNF32, NLRC5, IFI44L. We found 9 significant DMRs in the training set (**Table S1**). Methylation β values between high and low frailty ranged from -0.15 to 0.05 in these regions. As examples, 3

region plots showing DMRs in the *MX1*, *PARP9*, and *IFI44L* genes are shown in **Figure** 3.

Machine learning prediction on frailty by the selected 119 CpGs

Table 3: Performance of machine learning model predicting frailty in an HIV-infected population

		High frailty	(VACS index >50 vs. s	≤50)		Low frailty	(VACS index >16 vs. ≤	16)
	Tr	aining	Validation	<u> </u>	Tr	aining	Validation	
		Balanced		Balanced		Balanced		Balancec
Method	AUC	Accuracy	AUC	Accuracy	AUC	Accuracy	AUC	Accuracy
Random Forest	0.775	0.622	0.835 (0.792,0.879)	0.693	0.774	0.509	0.735 (0.688,0.782)	0.528
XGBoost	0.760	0.624	0.830 (0.786,0.874)	0.684	0.820	0.637	0.716 (0.669,0.762)	0.500
GLMNET	0.783	0.642	0.757 (0.701,0.813)	0.668	0.795	0.589	0.715 (0.667,0.763)	0.503
SVM	0.759	0.618	0.744 (0.685,0.802)	0.500	0.756	0.594	0.501 (0.442,0.560)	0.492

AUC: Area Under Curve

VACS: Veteran Aging Cohort Study

XGBoost: Extreme Gradient Boosting Tree

GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models

SVM: Support Vector Machines

245

246

247

248

249

250

251

252

253

254

242

243

244

In the training set, we developed our prediction models based on the selected 119 CpGs in the training set using four commonly used machine learning classification models: XGBoost, random forest, SVM and GLMNET (47-50). Performances of four prediction models are presented in **Table 3**. We found that AUCs ranged from 0.756 to 0.820 and balanced accuracies ranged from 0.509 to 0.642, suggesting that the 119 CpGs had good to excellent predictive performance on frailty. The performances of four models were mostly comparable. For predicting high frailty, GLMNET outperformed the three other models (AUC=0.783, balanced accuracy=0.642) while SVM performed slightly worse (AUC=0.759, balanced accuracy = 0.618). For the prediction of low frailty,

XGBoost performed the best among the four models (AUC=0.820, balanced accuracy=0.637) while SVM performed worst (AUC=0.756, balanced accuracy =0.594).

In the validation set, for the prediction of high frailty, random forest and XGBoost showed the best performance. AUC of random forest model was 0.835 (95%CI: 0.792, 0.879) and XGBoost was 0.830 (95%CI: 0.786, 0.874) for predicting high frailty.

Balanced accuracy was 0.69 and 0.68, respectively, for random forest and XGBoost (**Figure 4**). For the prediction of low frailty, XGBoost and random forest models also outperformed GLMNET and SVM. AUC was 0.735 (95%CI: 0.688, 0.782) for the random forest and 0.716 (95%CI: 0.669, 0762) for the XGBoost. The balanced accuracy was 0.528 and 0.500 for the random forest and XGBoost, respectively.

These results suggest that the selected panel of 119 CpG sites were able to predict frailty, and the prediction models performed better at predicting high frailty than predicting low frailty. Among four machine learning methods, SVM showed poor performance of predicting frailty in our samples.

DNAm score by 119 CpGs was significant associated with mortality

We constructed DNAm score based on the selected 119 CpGs, and we further assessed whether VACS index-related DNAm score were associated with mortality. In **Figure 5**, the Kaplan Meier curves during 10-year follow-up showed that the individuals with high DNAm score were at higher risk of mortality than those with low DNAm scores. After adjusting for confounding factors, our cox proportional hazards regression model showed that the hazard ratio of 5-year and 10-year mortality comparing high and low DNAm score groups were 1.40 (95%CI: 1.03-1.90, p=0.03) and 1.48 (95%CI: 1.10-

2.02, p=0.01) respectively. In conclusion, we found that the DNAm score constructed from the 119 selected CpGs was significantly associated with mortality.

Biological interpretations of 119 CpGs by gene ontology enrichment analysis

The selected panel of 119 CpGs were located within or near 73 genes. Gene ontology enrichment analysis using these 73 genes resulted in 9 significant pathways with FDR<0.05 (**Figure 6, Table 4**). These pathways included response to type I interferon response (FDR=1.05×10⁻⁷), innate immune response (FDR=3.45×10⁻⁵), cytokine response (FDR=3.69×10⁻³) and defense response to virus (**Figure 6**). Our findings suggested that the selected 119 CpG sites are biologically relevant to HIV pathogenesis and progression.

Table 4: Gene ontology term enrichment analysis of the selected CpG sites that predict frailty in an HIV infected population

				Fold		
Term	N	%	Genes	Enrichment	P value	FDR
GO:0034340~response to type I interferon	10	11.8	OAS2, IFITM1, IFIT3, MX1, NLRC5, HLA-F, XAF1, HLA-E, IRF7, PSMB8	28.1	6.62E-11	1.05E-07
GO:0045087~innate immune response	19	22.4	TRIM22, MAP4K2, IFITM1, TRIM25, MX1, GFI1, IFIT5, XAF1, LY86, PSMB8, TRIM14, PARP9, PLSCR1, OAS2, IFIT3, NLRC5, HLA-F, HLA-E, IRF7	5.0	2.17E-08	3.45E-05
GO:0051607~defense response to virus	11	12.9	TRIM22, PLSCR1, OAS2, IFITM1, TRIM25, IFIT3, MX1, IFI44L, NLRC5, IFIT5, IRF7	10.5	7.55E-08	1.20E-04
GO:0051707~response to other organism	18	21.2	TRIM22, PDE4B, EPO, IFITM1, NOTCH1, TRIM25, MX1, GFI1, IFIT5, IFI44L, LY86, PLSCR1, OAS2, IFIT3,	4.8	1.17E-07	1.85E-04

			CCDC88B, NLRC5, HLA-E, IRF7			
GO:0016032~viral process	19	22.4	TRIM22, IFITM1, TFRC, NOTCH1, TRIM25, MX1, PPIB, GFI1, IFIT5, IFI44L, TAP1, PSMB8, TRIM14, PLSCR1, OAS2, SLC1A5, IFIT3, NLRC5, IRF7 TRIM22, PLSCR1,	4.3	1.93E-07	3.07E-04
GO:0009615~response to virus	11	12.9	OAS2, IFITM1, TRIM25, IFIT3, MX1, IFI44L, NLRC5, IFIT5, IRF7	7.7	1.27E-06	2.02E-03
GO:0098542~defense response to other organism	13	15.3	TRIM22, PLSCR1, OAS2, IFITM1, TRIM25, IFIT3, MX1, CCDC88B, IFIT5, NLRC5, IFI44L, HLA-E, IRF7	5.8	1.94E-06	3.09E-03
GO:0034097~response to cytokine	16	18.8	TRIM22, EPO, IFITM1, TRIM25, MX1, GFI1, XAF1, PSMB8, PARP9, PLSCR1, OAS2, IFIT3, NLRC5, HLA-F, HLA-E, IRF7	4.4	2.32E-06	3.69E-03
GO:0034341~response to interferon-gamma	8	9.4	TRIM22, OAS2, IFITM1, TRIM25, NLRC5, HLA-F, HLA-E, IRF7	10.9	7.95E-06	1.26E-02

Discussion

In this study, we present evidences that DNAm marks in blood are predictive of frailty and are associated mortality in an HIV-positive population. We identified a panel of 119 CpG sites that were highly predictive for high frailty and moderately predictive for low frailty. We also found that the DNAm score constructed by these 119 CpGs was strongly associated with mortality in the HIV-positive population. More importantly, these

clinically informative 119 DNAm features lied in genes involved in HIV pathogenesis and progression. Thus, we discovered a panel of 119 DNAm biomarkers that add knowledge to the epigenetic mechanisms underlying frailty and mortality among people living with HIV.

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

We demonstrated the utility of using DNAm marks to predict frailty in HIV-positive individuals. We took the several steps to avoid overfitting in developing the prediction models: 1) model development and evaluation were conducted separately in training set and validation set. DNAm in two sets were profiled in different time with different platforms; 2) 10-fold cross validation were performed during training in each model. The performances of four machine learning methods were in general consistent except that the SVM did not perform well for low frailty. Our results suggested that this panel of CpG sites was relatively stable and robust although performances of predictive models differed using different methods. Of note, SVM showed the worst performance in predicting high and low frailty that highlights the importance of choosing appropriate machine learning method for model development. Compared to our previously reported a panel of 698 smoking-associated CpGs that are moderately predictive of frailty (15), the panel of 119 CpG sites in the present study includes fewer CpGs (119 CpGs) and shows greater prediction performance on frailty (AUC=0.73 for smoking-associated CpGs and AUC 0.83 for the VACS index-associated CpGs), suggesting that the panel of 119 CpG sites has greater clinical utility for frailty among people living with HIV. The improvement of prediction performance on frailty in the present study may be due to different strategies of CpG selections. In this study, the 119 CpGs are selected from the

entire blood methylome and may be more informative than the smoking-associated CpGs in our previous report.

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

We also found that the VACS index-related DNAm score derived from the 119 CpGs is strongly associated with mortality. This result provides further knowledge of epigenetic profile into previous report that VACS index is predictive of mortality in people who live with HIV (53). The result is also consistent with previous literature showing that DNAm marks in blood predict mortality in the general population (39). Interestingly, we found no overlapped CpG between our predictive panel and the previously identified CpGs for all-cause mortality that included CpGs associated with a variety of diseases such as diabetes and cancer (39). The discrepancy suggest that methylation-based prediction of mortality may be relevant to causal disease. A recent study reports a significant overlap of mortality-associated CpGs and aging-associated CpGs (Lund et al, 2019). We found no overlapped CpG site between our mortalityrelated 119 CpG panel and aging-related 353 CpGs in epigenetic clock (7), suggesting that epigenetic mechanisms in HIV-related mortality differ from aging-related mortality. Most importantly, this panel of 119 CpG sites are biologically meaningful and may shed light on our understanding of the biological mechanisms of frailty for HIVpositive individuals. The majority of the 119 CpG sites were located within or near genes that are involved in known HIV pathology and progression. The results from DMR analysis are corresponding to some of the significant genes for frailty. For example, cg26312951, cg22862003 and cg21549285 from the 119 CpG sites are located in the MX1 gene (Interferon-Induced GTP-Binding Protein Mx1) and were negatively

associated with frailty. A DMR on MX1 also showed a significant with frailty. MX1

encodes a GTP-metabolizing protein induced by interferon I and II and is involved in interferon gamma signaling and Toll-like signaling pathway. Multiple CpGs near the *HLA-F* and *HLA-E* genes are part of the predictive panel, and these two genes are actively involved in immune response (54). Our previously reported HIV-associated CpG site, cg07839457 in the *NLRC5* gene is also a member of the predictive panel on frailty (25). Other interesting gene regions reveled by DMR analysis include *PARP9* and *IFI44L*, which both genes are involved in *HIV pathogenesis*. The biological relevance of these 119 CpG sites was further supported by the gene ontology enrichment analysis. The top enriched pathways such as type I interferon response and cytokine response may point out important biological pathways that leads to frailty and increased risk of mortality among people living with HIV.

We acknowledge several limitations in this study. The generalizability of the selected CpG sites may be limited since our samples were predominantly middle-aged men, which may not generalize to frailty in a different age group. All samples in our study are HIV-positive and the identified CpGs have a limited application to HIV-negative population as we discussed above. Future studies in diverse populations is warranted to validate the selected methylation features. Lastly, the prediction of low frailty is moderate due to imbalanced sample distribution in our present study. We expect that including more samples with low frailty will improve the predictive performance.

Conclusions

We identified a panel of 119 predictive DNAm features in blood that are associated with frailty and mortality among people living with HIV. These DNAm features may serve as biomarkers to discriminate high and low frailty groups and may help to prioritize genes to better understand the mechanisms of frailty in HIV-positive population. These DNAm features have potential to serve as biomarkers to monitor HIV progression in future clinical care.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

prediction

Legends Figure 1: Flowchart of analytical procedures on selection of CpG sites in peripheral blood methylome, machine learning prediction models to predict frailty, DNA methylation score to assess mortality, and gene ontology enrichment analysis Figure 2: Manhattan and quantile-quantile plots on Veteran Aging Cohort Study (VACS) index (λ =1.038) in the training set; blue line indicates False Discovery Rate (FDR)=0.05 Figure 3: Differentially methylation regions (DMRs) are associated with frailty, measured by Veteran Aging Cohort Study (VACS) index. a: MX1 regional plot showing methylation beta value among subjects with VACS index > 50 and VACS index ≤ 50 in the training set. b: IFI11L regional plot showing methylation beta value among subjects with VACS index > 50 and VACS index ≤ 50 in the training set. c: PARP9 regional plot showing methylation beta value among subjects with VACS index > 50 and VACS index ≤ 50 in the training set Figure 4: Receiver operating characteristic curve by XGBoost prediction model on HIV frailty; a) Predicting high HIV frailty (VACS index >50 vs. ≤50), Area Under Curve (AUC): 0.830 (95% CI: 0.786,0.874); b) Predicting low HIV frailty (VACS index >16 vs. ≤16), AUC: 0.735 (95% CI: 0.688,0.782) Figure 5: Kaplan-Meier curves comparing high and low HIV frailty methylation score groups. Methylation score is calculated by 119 selected probes. High methylation score group has methylation score >=0, while low methylation score group <0. Figure 6: Gene ontology enrichment analysis of 119 CpG probes (FDR<0.05) for

Figure S1: Distribution of Veteran Aging Cohort Study index (VACS index) between training set and testing set

Table 1: Study sample characteristics

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIV-positive veteran population

Table 3: Performance of machine learning model predicting high and low frailty in an HIV-positive population

Table 4: Gene ontology term enrichment analysis of the selected 119 CpG sites that predict frailty in an HIV-positive population

Table S1: Differentially methylated regions between high and low frailty in training set

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIV-infected veteran population

infected vetera	п рори	iation							
СрG	Chr	Position	Gene	Gene group	Relation to CpG Island	Effect size	SE	P value	FDR*
cg01309328	6	32811253	PSMB8	Body	N_Shore	-5.30	0.888	4.44E-09	9.32E-04
cg08099136	6	32811251	PSMB8	Body	N_Shore	-4.77	0.800	4.63E-09	9.32E-04
cg26312951	21	42797847	MX1	TSS200;5UTR	N_Shore	-2.46	0.417	6.40E-09	9.32E-04
cg08818207	6	32820355	TAP1	Body	N_Shore	-3.40	0.627	9.17E-08	1.00E-02
cg08122652	3	12228193 9	PARP9	5UTR;TSS1500	N_Shore	-1.79	0.341	2.18E-07	1.45E-02
cg07352001	10	44144445	ZNF32	TSS200;TSS1500	Island	- 14.30	2.730	2.31E-07	1.45E-02
cg07325529	6	6613762	LY86	Body		20.70	3.980	2.77E-07	1.45E-02
cg16242615	19	4059988	ZBTB7 A	5UTR	Island	-6.27	1.200	2.85E-07	1.45E-02
cg00533183	6	32810742	PSMB8	Body	N_Shore	-5.81	1.120	3.18E-07	1.45E-02
cg12649038	10	11628253 4	ABLIM 1	5UTR		5.03	0.973	3.32E-07	1.45E-02
cg08926253	11	614761	IRF7	Body	Island	-2.91	0.571	4.94E-07	1.96E-02
cg03038262	11	315262	IFITM1	3UTR	N_Shore	-2.86	0.565	5.83E-07	2.12E-02
cg07839457	16	57023022	NLRC5	TSS1500	N_Shore	-1.99	0.396	6.55E-07	2.12E-02
cg22930808	3	12228188 1	PARP9	5UTR	N_Shore	-1.54	0.306	6.78E-07	2.12E-02
cg03607951	1	79085586	IFI44L	TSS1500		-2.00	0.398	7.41E-07	2.16E-02
cg08260450	6	34993987	ANKS1 A	Body		6.35	1.270	8.43E-07	2.30E-02
cg03917473	17	38764244				9.10	1.840	1.04E-06	2.67E-02
cg18234224	1	17291785 1				6.59	1.350	1.34E-06	3.22E-02
cg06188083	10	91093005	IFIT3	Body		-2.02	0.414	1.40E-06	3.22E-02
cg23570810	11	315102	IFITM1	Body	N_Shore	-2.31	0.475	1.58E-06	3.41E-02
cg03816851	22	18324769	MICAL 3	Body	Island	10.30	2.120	1.64E-06	3.41E-02
cg20676542	17	54991456	TRIM2 5	TSS200	Island	-3.02	0.629	2.10E-06	4.17E-02
cg05019807	9	13941039 3	NOTCH 1	Body	N_Shore	5.97	1.260	2.70E-06	5.07E-02
cg03753191	13	43566902	EPSTI1	TSS1500	S_Shore	-5.39	1.140	2.88E-06	5.07E-02
cg01971407	11	313624	IFITM1	TSS1500	N_Shelf	-3.53	0.745	2.90E-06	5.07E-02
cg03359362	19	47289611	SLC1A 5	TSS1500;Body;5 UTR	N_Shore	- 12.60	2.670	3.13E-06	5.10E-02
cg22116398	5	196162			S_Shore	5.15	1.090	3.15E-06	5.10E-02
cg26922780	16	88769443	RNF16 6	Body	N_Shelf	4.27	0.907	3.28E-06	5.12E-02
cg15748006	2	9772375	YWHA Q	TSS1500	S_Shore	4.45	0.949	3.45E-06	5.20E-02

cg22862003	21	42797588	MX1	TSS1500;5UTR	N_Shore	-1.66	0.356	3.88E-06	5.65E-02
cg21366673	6	30459512	HLA-E	Body	S_Shore	-4.19	0.900	4.04E-06	5.69E-02
cg05588757	2	95825608	ZNF51 4	TSS1500	Island	- 19.40	4.220	5.25E-06	6.64E-02
cg06872964	1	79085250	IFI44L	TSS1500		-1.92	0.416	5.26E-06	6.64E-02
cg06376949	10	91173811	IFIT5	TSS1500	N_Shore	-3.21	0.698	5.29E-06	6.64E-02
cg01154505	2	11294040 9	FBLN7	Body	S_Shore	6.16	1.340	5.32E-06	6.64E-02
cg01871595	13	39336304	FREM2	Body		6.90	1.500	5.59E-06	6.78E-02
cg05696877	1	79088769	IFI44L	5UTR		-1.21	0.265	6.01E-06	6.94E-02
cg24497541	1	55352819	DHCR2 4	1stExon;5UTR	Island	-9.81	2.150	6.12E-06	6.94E-02
cg11829870	22	50988451	KLHDC 7B	3UTR;1stExon	S_Shore	-3.63	0.795	6.28E-06	6.94E-02
cg13720750	5	11230916 7			N_Shelf	7.28	1.600	6.37E-06	6.94E-02
cg18255813	6	7195966	RREB1	Body		9.38	2.060	6.76E-06	6.94E-02
cg21549285	21	42799141	MX1	5UTR	S_Shore	-1.01	0.224	7.08E-06	6.94E-02
cg14945867	14	54908007	CNIH	1stExon	Island	- 29.70	6.550	7.16E-06	6.94E-02
cg09026253	11	313267	IFITM1	TSS1500	S_Shore	-3.48	0.768	7.25E-06	6.94E-02
cg14651616	11	64563992	MAP4 K2	Body		-6.98	1.540	7.27E-06	6.94E-02
cg24082730	3	12607636 6	KLF15	TSS200	Island	- 10.90	2.410	7.31E-06	6.94E-02
cg16302816	11	16834800	PLEKH A7	Body		6.50	1.440	7.49E-06	6.96E-02
cg01765174	9	10088096 0	TRIM1 4	Body	N_Shore	-4.47	0.993	8.35E-06	7.60E-02
cg10552523	11	313478	IFITM1	TSS1500	N_Shelf	-3.14	0.702	9.42E-06	8.40E-02
cg19025187	3	19580825 5	TFRC	5UTR	N_Shore	-6.73	1.510	1.07E-05	9.16E-02
cg21081878	21	38334730	HLCS	5UTR	N_Shelf	3.49	0.785	1.08E-05	9.16E-02
cg14299044	10	19972179				5.32	1.200	1.09E-05	9.16E-02
cg24871132	3	14968884 6	PFN2	TSS200	Island	- 21.70	4.900	1.17E-05	9.55E-02
cg27294701	16	88107336	BANP	Body	Island	7.04	1.590	1.18E-05	9.55E-02
cg09296453	6	29692035	HLA-F	Body	Island	-3.24	0.735	1.31E-05	1.04E-01
cg16400434	11	73882363	PPME1 ;C2CD3	TSS200;TSS1500	Island	- 25.60	5.850	1.46E-05	1.13E-01
cg16656286	17	4981603	ZFP3	TSS200	Island	22.40	5.130	1.52E-05	1.13E-01
cg26480543	19	55629279	PPP1R 12C	TSS1500	S_Shore	-7.33	1.680	1.52E-05	1.13E-01
cg19371652	12	11341588 3	OAS2	TSS1500		-3.59	0.822	1.52E-05	1.13E-01
cg09597638	17	3907349			N_Shore	-5.48	1.260	1.56E-05	1.14E-01
cg00994629	14	22694547				-7.44	1.710	1.62E-05	1.16E-01

cg02314339	10	91020653				-4.35	1.010	1.86E-05	1.29E-01
cg21468416	9	12701991 4	NEK6	1stExon;TSS150 0;5UTR	N_Shore	6.61	1.530	1.89E-05	1.29E-01
cg12149905	3	61547208	PTPRG	TSS200	Island	- 12.20	2.820	1.89E-05	1.29E-01
cg20927242	6	29692011	HLA-F	Body	Island	-7.14	1.660	1.97E-05	1.32E-01
cg03332034	16	1823786	EME2; MRPS3 4	TSS1500	Island	- 12.30	2.870	2.12E-05	1.36E-01
cg05489271	12	12387169 5	SETD8	Body	N_Shelf	7.83	1.820	2.13E-05	1.36E-01
cg25843003	6	31431312	HCP5	3UTR		-3.29	0.768	2.19E-05	1.36E-01
cg14090510	7	64839023	ZNF92	5UTR;Body	Island	- 14.70	3.440	2.21E-05	1.36E-01
cg25467833	1	21233506 1				4.86	1.140	2.28E-05	1.36E-01
cg03725115	6	30458102	HLA-E	Body	Island	-5.09	1.190	2.29E-05	1.36E-01
cg15620384	6	34164405			Island	-6.69	1.570	2.34E-05	1.36E-01
cg08450404	19	58326441	ZNF55 2	TSS200	S_Shore	-8.37	1.960	2.35E-05	1.36E-01
cg06927297	12	11717588 9	RNFT2	TSS200;TSS1500	Island	- 27.60	6.460	2.36E-05	1.36E-01
cg21684411	6	31431573	HCP5	3UTR		-6.71	1.570	2.40E-05	1.36E-01
cg20998539	17	62208374	ERN1	TSS1500	S_Shore	-7.32	1.720	2.42E-05	1.36E-01
cg25138854	1	9555557			Island	-7.03	1.650	2.45E-05	1.36E-01
cg13250752	4	13828199 2				-6.09	1.430	2.46E-05	1.36E-01
cg26562691	16	23850404	PRKCB	Body	S_Shelf	6.87	1.620	2.47E-05	1.36E-01
cg23677352	4	14971567 5				-7.92	1.860	2.49E-05	1.36E-01
cg22107533	15	45028083	TRIM6 9	TSS1500		-3.14	0.739	2.53E-05	1.36E-01
cg06412917	12	12485884 4	NCOR2	Body	S_Shelf	6.47	1.520	2.57E-05	1.37E-01
cg01190666	20	62204908	PRIC28 5	5UTR	N_Shore	-3.47	0.818	2.67E-05	1.40E-01
cg11977562	13	11484529 7	RASA3	Body	N_Shelf	7.05	1.660	2.70E-05	1.40E-01
cg13304609	1	79085162	IFI44L	TSS1500		-1.54	0.364	2.72E-05	1.40E-01
cg01537765	19	42914828	LIPE	Body	Island	22.00	5.210	2.75E-05	1.40E-01
cg08275025	11	314493	IFITM1	Body	N_Shore	-4.98	1.180	2.78E-05	1.40E-01
cg05362517	13	37393368	RFXAP	5UTR;1stExon	Island	- 13.80	3.260	2.92E-05	1.42E-01
cg21145248	5	17681667 9	SLC34 A1	Body		6.04	1.430	2.94E-05	1.42E-01
cg07537655	6	16141561 2	MAP3 K4	Body	S_Shelf	1.77	0.419	2.95E-05	1.42E-01
cg26912671	1	66458803	PDE4B	1stExon		10.70	2.540	3.01E-05	1.42E-01

cg11905821	6	31770932	LSM2	Body	N_Shelf	11.80	2.800	3.05E-05	1.42E-01
cg06202053	11	64109021	CCDC8 8B	Body	N_Shore	-5.84	1.390	3.09E-05	1.42E-01
cg13794687	7	12330239 9	LMOD 2	Body		6.73	1.600	3.11E-05	1.42E-01
cg23892836	6	29692085	HLA-F	Body	Island	-3.19	0.759	3.12E-05	1.42E-01
cg15331332	6	29692111	HLA-F	Body	S_Shore	-3.53	0.840	3.12E-05	1.42E-01
cg15804432	15	64454965	PPIB	Body	Island	-4.27	1.020	3.15E-05	1.42E-01
cg09251764	17	6659070	XAF1	TSS200		-5.73	1.370	3.23E-05	1.44E-01
cg20893717	7	10031819 0	EPO	TSS1500	Island	13.80	3.290	3.26E-05	1.44E-01
cg08159663	16	57022486	NLRC5	TSS1500	N_Shore	-3.44	0.821	3.29E-05	1.44E-01
cg10019429	19	32836659	ZNF50 7	1stExon;5UTR	Island	- 17.20	4.120	3.55E-05	1.54E-01
cg11791770	11	611791	PHRF1	3UTR	Island	-6.52	1.560	3.64E-05	1.56E-01
cg11653134	2	66805547			S_Shore	-4.24	1.020	3.81E-05	1.61E-01
cg06981309	3	14626095 4	PLSCR1	5UTR	N_Shore	-1.96	0.471	3.84E-05	1.61E-01
cg07168939	8	14376341 2	PSCA	Body		-5.88	1.420	3.88E-05	1.61E-01
cg04611649	2	15268124 0	ARL5A	5UTR	N_Shelf	7.42	1.790	4.04E-05	1.66E-01
cg16297569	1	92952517	GFI1	TSS1500;TSS200	Island	-8.34	2.020	4.16E-05	1.70E-01
cg01518846	6	26246970	HIST1H 4G	1stExon	Island	- 17.50	4.240	4.41E-05	1.74E-01
cg26852894	4	11157341				6.31	1.530	4.42E-05	1.74E-01
cg06811183	3	48510438	SHISA5	3UTR		-8.23	2.000	4.42E-05	1.74E-01
ch.10.130520 3R	10	63407435				-8.63	2.090	4.43E-05	1.74E-01
cg12461141	11	5710654	TRIM2 2	TSS1500		-3.40	0.829	4.79E-05	1.87E-01
cg13149600	21	43374220	C2CD2	TSS1500	S_Shore	-9.35	2.280	4.83E-05	1.87E-01
cg12660813	1	3192343	PRDM 16	Body	N_Shelf	7.28	1.780	4.96E-05	1.89E-01
cg24447788	19	795310			N_Shore	11.30	2.760	5.02E-05	1.89E-01
cg13861758	9	13814809 9			N_Shelf	5.08	1.240	5.02E-05	1.89E-01
cg09950208	10	13084123 5				-4.99	1.220	5.24E-05	1.95E-01
cg01482620	19	48835971	TMEM 143	3UTR	N_Shore	18.40	4.500	5.28E-05	1.95E-01
cg03634735	7	1992524	MAD1 L1	Body	S_Shore	6.19	1.520	5.37E-05	1.97E-01

^{*}FDR: False discovery

rate 403

Table S1: Differentially methylated regions between high and low fraity in training set

chr	start	end	value	area	Number of CpG	p.value	fwer	Gene.Symbol	FDR	СрG
										cg0095925
3	122281881	122281975	-0.068	0.203	3	2.30E-07	0.001	DTX3L,PARP9	1.03E-04	cg0812265
										cg2293080
										cg0620247
12	11700321	11700489	-0.054	0.162	3	1.61E-06	0.006	LINC01252	3.60E-04	cg1823223
										cg1965111
										cg0045821
4	70000760	70110101	0.020	0.454	4	1 175 05	0.040	15144 151441	4 755 00	cg0107965
1	79088769	79118191	-0.039	0.154	4	1.17E-05	0.049	IFI44,IFI44L	1.75E-03	cg0569687
										cg0710745
21	42707500	42707047	0.046	0.003	2	2 415 05	0.001	A 4 V 1	2 (05 02	cg2286200
21	42797588	42797847	-0.046	0.092	2	2.41E-05	0.081	MX1	2.68E-03	cg2631295
										cg0085590
										cg0360795
1	79085162	79085765	-0.034	0.168	5	2.99E-05	0.122	IFI44L	2.68E-03	cg0687296
										cg1330460
										cg1798050
										cg2004532
11	319555	319718	-0.036	0.109	3	4.73E-05	0.166	IFITM3	2.80E-03	cg0912203
										cg1799036
										cg0188698
										cg0197140
										cg0458201
										cg0543200
11	312518	313624	-0.023	0.230	10	4.89E-05	0.194	IFITM1	2.80E-03	cg0902625
	312310	31332 1	0.023	0.230	10	1.032 03	0.13		2.002 05	cg1055252
										cg1169451
										cg2056689
										cg2296345
										cg2703210
										cg1204794
										cg1501352
										cg2505033
										cg2733166
										cg0303826
11	314493	317767	-0.021	0.228	11	5.01E-05	0.195	IFITM1	2.80E-03	cg0800073
										cg0827502
										cg1637909
										cg1843456
										cg2168621
										cg2357081
21	42798747	42799141	-0.041	0.083	2	5.95E-05	0.197	MX1	2.96E-03	cg0892420
										cg2154928

406 List of abbreviations 407 AUC: Area Under Curve 408 CI: Confidence interval 409 DMR: differentially methylated region 410 DNA: Deoxyribonucleic acid 411 **DNAm: DNA methylation** 412 DAVID: Database for Annotation, Visualization and Integrated Discovery 413 EWAS: epigenome-wide association study 414 FDR: False discovery rate 415 FWER: Family-wise error rate GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models 416 417 GO: Gene ontology 418 HIV: Human immunodeficiency virus 419 HM450K: Human Methylation 450K BeadChip 420 NK: Natural killer 421 PC: Principal component 422 QC: Quality control 423 **SVM: Support Vector Machines** 424 VACS: Veterans Aging Cohort Study 425 VACS index: Veterans Aging Cohort Study index 426 XGBoost: Extreme Gradient Boosting Tree 427

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

Declarations Ethics approval and consent to participate The study was approved by the committee of the Human Research Subject Protection at Yale University and the Institutional Research Board Committee of the Connecticut Veteran Healthcare System. All subjects provided written consents. Availability of data and materials Demographic and clinical variables and DNAm data for the VACS samples were submitted to GEO dataset (GSE117861) and are available to the public. All codes for analysis are also available upon a request to the corresponding author. Competing interests The authors declare that they have no competing interests. **Funding** The project was supported by the National Institute on Drug Abuse (R03DA039745, R01DA038632, R01DA047063, R01DA047820) and the National Center for Post-Traumatic Stress Disorder, USA. Authors' contributions CS was responsible for data analysis and manuscript preparation. ACJ provided DNA samples, clinical data, and contributed to manuscript preparation. XZ was responsible for the bioinformatics data processing. VM involved clinical data collection and manuscript preparation. DH and EJ contributed to analytical approach and the manuscript preparation. KX was responsible for the study design, study protocol, sample preparation, data analysis, interpretation of findings, and manuscript preparation.

Acknowledgements

The authors appreciate the support of the Veteran Aging Study Cohort Biomarker Core and Yale Center of Genomic Analysis.

References

- 459 1. Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV
- infection is independently associated with frailty in middle-aged HIV type 1-infected individuals
- compared with similar but uninfected controls. AIDS. 2016;30(2):241-50.
- 2. Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: A
- 463 review. Eur J Intern Med. 2016;31:3-10.
- 464 3. Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based
- 465 biomarkers in colorectal cancer: a systematic review. Biochimica et Biophysica Acta (BBA)-
- 466 Reviews on Cancer. 2016;1866(1):106-20.
- 467 4. Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of
- schizophrenia and bipolar disorder: a systematic review. BMC genetics. 2016;17(1):27.
- 469 5. Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: A systematic
- 470 review on DNA methylation mechanisms. Journal of Psychosomatic Research. 2017;92:34-44.
- 471 6. Li M, D'Arcy C, Li X, Zhang T, Joober R, Meng X. What do DNA methylation studies tell us
- about depression? A systematic review. Translational psychiatry. 2019;9(1):68.
- 473 7. Horvath S. DNA methylation age of human tissues and cell types. Genome biology.
- 474 2013;14(10):3156.
- 475 8. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
- ageing. Nature Reviews Genetics. 2018:1.
- 477 9. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide
- 478 methylation profiles reveal quantitative views of human aging rates. Molecular cell.
- 479 2013;49(2):359-67.
- 480 10. Liu C, Marioni RE, Hedman ÅK, Pfeiffer L, Tsai P-C, Reynolds LM, et al. A DNA
- 481 methylation biomarker of alcohol consumption. Molecular psychiatry. 2018;23(2):422.
- 482 11. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related
- differential DNA methylation: 27K discovery and replication. The American Journal of Human
- 484 Genetics. 2011;88(4):450-7.
- 485 12. Gao X, Zhang Y, Breitling LP, Brenner H. Relationship of tobacco smoking and smoking-
- related DNA methylation with epigenetic age acceleration. Oncotarget. 2016;7(30):46878-89.
- 487 13. Joubert BR, Håberg SE, Nilsen RM, Wang X, Vollset SE, Murphy SK, et al. 450K
- 488 epigenome-wide scan identifies differential DNA methylation in newborns related to maternal
- smoking during pregnancy. Environmental health perspectives. 2012;120(10):1425-31.
- 490 14. Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Frontiers in genetics.
- 491 2013;4:132.
- 492 15. Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, et al. Machine learning
- 493 selected smoking-associated DNA methylation signatures that predict HIV prognosis and
- 494 mortality. 2018;10(1):155.
- 495 16. Zhang R, Miao Q, Wang C, Zhao R, Li W, Haile CN, et al. Genome-wide DNA methylation
- analysis in alcohol dependence. Addiction biology. 2013;18(2):392-403.
- 497 17. Kraiczy J, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, et al. DNA methylation
- 498 defines regional identity of human intestinal epithelial organoids and undergoes dynamic
- 499 changes during development. Gut. 2019;68(1):49-61.

- 18. Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-Wide
- Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic
- 502 Steatosis. Gastroenterology. 2017;153(4):1096-106.e2.
- 503 19. Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and cancer diagnosis.
- International journal of molecular sciences. 2013;14(7):15029-58.
- 505 20. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA
- 506 methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer
- 507 cell. 2010;17(1):13-27.
- 508 21. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, et al. Molecular
- subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast
- 510 cancer research. 2010;12(3):R36.
- 511 22. Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nature
- 512 Reviews Genetics. 2019;20(2):109-27.
- 513 23. Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer
- therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403-18.
- 515 24. Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella Jr FJ, et al.
- 516 Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-
- related phenotype of men with or at risk for HIV infection. The Journal of infectious diseases.
- 518 2016;215(2):228-37.
- 519 25. Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, et al. Epigenome-wide differential
- 520 DNA methylation between HIV-infected and uninfected individuals. Epigenetics.
- 521 2016;11(10):750-60.
- 522 26. Chen J, Huang Y, Hui Q, Mathur R, Gwinn M, So-Armah K, et al. Epigenetic Associations
- 523 with Estimated Glomerular Filtration Rate (eGFR) among Men with HIV Infection. Clin Infect Dis.
- 524 2019.
- 525 27. Mathur R, Hui Q, Huang Y, Gwinn M, So-Armah K, Freiberg MS, et al. DNA Methylation
- 526 Markers of Type 2 Diabetes Mellitus Among Male Veterans With or Without Human
- 527 Immunodeficiency Virus Infection. J Infect Dis. 2019;219(12):1959-62.
- 528 28. Breitling LP, Saum K-U, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated
- with the epigenetic clock but not with telomere length in a German cohort. Clinical Epigenetics.
- 530 2016;8(1):21.
- 531 29. Sanchez-Conde M, Rodriguez-Centeno J, Dronda F, Lopez JC, Jimenez Z, Berenguer J, et
- al. Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.
- 533 Epigenomics. 2019;11(5):501-9.
- 534 30. Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock.
- 535 The Journal of infectious diseases. 2015;212(10):1563-73.
- 536 31. Rickabaugh TM, Baxter RM, Sehl M, Sinsheimer JS, Hultin PM, Hultin LE, et al.
- Acceleration of age-associated methylation patterns in HIV-1-infected adults. PloS one.
- 538 2015;10(3):e0119201.
- 539 32. Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al.
- 540 Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age
- and epigenetic targeting of HLA. Molecular cell. 2016;62(2):157-68.

- 33. Nelson KN, Hui Q, Rimland D, Xu K, Freiberg MS, Justice AC, et al. Identification of HIV
- 543 infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive,
- 544 treatment-naive U.S. veterans. AIDS. 2017;31(4):571-5.
- 34. Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, et al. DNA methylation age
- of blood predicts all-cause mortality in later life. Genome biology. 2015;16(1):25.
- 35. Marioni RE, Harris SE, Shah S, McRae AF, von Zglinicki T, Martin-Ruiz C, et al. The
- 548 epigenetic clock and telomere length are independently associated with chronological age and
- mortality. International journal of epidemiology. 2016;45(2):424-32.
- 550 36. Perna L, Zhang Y, Mons U, Holleczek B, Saum K-U, Brenner H. Epigenetic age
- acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort.
- 552 Clinical epigenetics. 2016;8(1):64.
- 553 37. Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, et al. DNA methylation
- age is associated with mortality in a longitudinal Danish twin study. Aging Cell. 2016;15(1):149-
- 555 54.
- 556 38. Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a
- 557 predictor of disease and mortality risk: a systematic review and meta-analysis. Clin Epigenetics.
- 558 2019;11(1):62.
- 39. Zhang Y, Wilson R, Heiss J, Breitling LP, Saum K-U, Schöttker B, et al. DNA methylation
- signatures in peripheral blood strongly predict all-cause mortality. Nature communications.
- 561 2017;8:14617.
- 562 40. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally
- 563 generalizable risk index for mortality after one year of antiretroviral therapy. Aids.
- 564 2013;27(4):563-72.
- 565 41. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans
- aging cohort study (VACS): overview and description. 2006;44(8 Suppl 2):S13.
- Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan S-T, et al. A coherent approach for
- analysis of the Illumina HumanMethylation450 BeadChip improves data quality and
- performance in epigenome-wide association studies. 2015;16(1):37.
- 43. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al.
- 571 Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA
- 572 methylation microarrays. 2014;30(10):1363-9.
- 573 44. Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting to
- identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol.
- 575 2012;41(1):200-9.
- 576 45. Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, et al. The VACS index
- 577 predicts mortality in a young, healthy HIV population starting highly active antiretroviral
- therapy. Journal of acquired immune deficiency syndromes (1999). 2014;65(2):226.
- 579 46. Kuhn MJJoss. Building predictive models in R using the caret package. 2008;28(5):1-26.
- 580 47. Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of statistical learning: data
- mining, inference and prediction. The Mathematical Intelligencer. 2005;27(2):83-5.
- 582 48. Kotsiantis SB, Zaharakis I, Pintelas P. Supervised machine learning: A review of
- 583 classification techniques. Emerging artificial intelligence applications in computer engineering.
- 584 2007;160:3-24.

- 585 49. Chen T, Guestrin C, editors. Xgboost: A scalable tree boosting system. Proceedings of the 586 22nd acm sigkdd international conference on knowledge discovery and data mining; 2016: 587 ACM. 588 50. Ogutu JO, Piepho H-P, Schulz-Streeck T. A comparison of random forests, boosting and
- 589 support vector machines for genomic selection. BMC Proc. 2011;5 Suppl 3(Suppl 3):S11-S.
- 590 51. Brodersen KH, Ong CS, Stephan KE, Buhmann JM, editors. The balanced accuracy and its 591 posterior distribution. 2010 20th International Conference on Pattern Recognition; 2010: IEEE.
- 592 Fresno C, Fernández EAJB. RDAVIDWebService: a versatile R interface to DAVID.
- 593 2013;29(21):2810-1.
- 594 53. Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, et al. Predictive
- 595 accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North
- 596 American cross cohort analysis. Journal of acquired immune deficiency syndromes (1999).
- 597 2013;62(2):149-63.

601

602

603

604

605

606

607

608

609

610


611

612

613

614

- 598 54. O'Callaghan CA, Bell JIJIr. Structure and function of the human MHC class Ib molecules
- 599 HLA-E, HLA-F and HLA-G. 1998;163(1):129-38.









Figure 2










Figure 4




Figure 5

